Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 10:17 PM
Ignite Modification Date:
2025-12-26 @ 10:17 PM
NCT ID:
NCT02219412
Eligibility Criteria:
Inclusion Criteria:
* Provision of informed consent prior to any study specific procedures.
* Aged \>18 years.
* Documented stable coronary artery disease.
* Currently receiving dual-antiplatelet therapy with aspirin 100mg/d and clopidogrel 75mg/d.
Exclusion Criteria:
* History of acute coronary syndrome within 12 months of screening.
* History of percutaneous coronary intervention within 12 months of screening.
* Any indication (eg, atrial fibrillation,prosthetic heart valve, or coronary stent) for antithrombotic therapy(eg, warfarin, clopidogrel, or aspirin dose other than 75 to 100 mg/during the study period).
* AA induced platelet aggregation rate \>20% on aspirin+clopidogrel measured by light transmission platelet aggregation test with the past 3 months.
* Congestive heart failure or left ventricular ejection fraction \<35%.
* Forced expiratory volume in the first second forced vital capacity below the lower limits of normal.
* Bleeding diathesis or severe pulmonary disease.
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Hypersensitivity to ticagrelor or any of the excipients.
* Severe hepatic impairment.
* Pregnancy.
* Current smoking.
* Platelet count \<100 000/mm3 or hemoglobin \<10 g/dL.
* HemoglobinA1c \>10%.
* History of drug addiction or alcohol abuse in the past 2 years.
* Need for nonsteroidal anti-inflammatory drug.
* Creatinine clearance\<30 mL/min.
* Concomitant therapy with moderate or strong cytochrome P450 3A inhibitors, substrates, or strong cytochrome P450 3A inducers.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT02219412
Study Brief:
Protocol Section:
NCT02219412